Analysis of Erythropoietic Protoporphyria (EPP) Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Porphyria is a genetic metabolic disorder with inborn error of heme biosynthesis. Heme is essential component of blood cells which carry oxygen and support in breaking down chemical compounds in the liver.
Erythropoietic protoporphyria (EPP) is a type of porphyria which is a rare disease associated with an impaired activity of ferrocheletase (FECH) an important enzyme in heme production. The worldwide reported prevalence for Erythropoietic protoporphyria is rages from 1 in 75,000 to 1 in 200,000 and it is the most common porphyria in children.
Drug therapies used to treat Erythropoietic protoporphyria (EPP) includes antihistamines, analgesics, hormonal therapy, phototherapy, sunscreens, and antioxidants. Hormonal therapy is a recent emerging treatment in an erythropoietic protoporphyria (EPP) treatment market approved by the US FDA.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
The significantly increasing unmet need of advanced erythropoietic protoporphyria (EPP) treatment therapeutics for the treatment of erythropoietic protoporphyria (EPP) is expected to propel the growth of the global erythropoietic protoporphyria (EPP) treatment market.
In addition, growing prevalence of erythropoietic protoporphyria (EPP) in children is expected to fuel the growth of erythropoietic protoporphyria (EPP) treatment market. Novel therapeutic development and approval is expected to propel an erythropoietic protoporphyria (EPP) treatment market in the future.
However, higher treatment cost and lack of standardize healthcare facilities are the key factors expected to slow down the growth of erythropoietic protoporphyria (EPP) treatment market in the emerging economies.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
An erythropoietic protoporphyria (EPP) treatment market is expected to experience moderate growth over the forecast period owing to technical advancements in the diagnosis and treatment of an erythropoietic protoporphyria (EPP). Leading developers are focusing on development of novel therapeutics for erythropoietic protoporphyria (EPP). Among therapy types, first-line hormonal therapies segment is expected to hold the major market share in an erythropoietic protoporphyria (EPP) treatment market.
Recently, in last quarter of 2019, FDA has approved Scenesse® (afamelanotide subcutaneous implant) a new treatment for erythropoietic protoporphyria (EPP) manufactured by the Clinuvel Pharmaceuticals ALS, Australia.
Among distribution channels segment, retail pharmacy segment is expected to be the leading revenue generating segment owing to high patient foot fall in erythropoietic protoporphyria (EPP) treatment market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Geographically, global erythropoietic protoporphyria (EPP) treatment market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa. North America is a prominent region in an erythropoietic protoporphyria (EPP) treatment market owing to novel treatment advancements.
European erythropoietic protoporphyria (EPP) treatment market is a second most lucrative region due to early diagnosis and treatment adoption. In addition, East Asia region substantially has higher market growth rate owing to large base of population. Middle East and Africa is expected to be least-lucrative market owing to poor healthcare infrastructure and low awareness.
The global market for erythropoietic protoporphyria (EPP) treatment is consolidated with few market players. Examples of some of the primary key players operating in the global erythropoietic protoporphyria (EPP) treatment market are Clinuvel Pharmaceuticals ALS, Johnson and Johnson, Tishcon Corp., L'Oréal S.A., Fenton Pharmaceuticals Ltd., In-Life Co. Pfizer Inc., Mylan N.V., Teva Pharmaceuticals, Sun Pharma Ltd., and among others.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
An erythropoietic protoporphyria (EPP) treatment market can be segmented into therapy type, distribution channels and geography.
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesPre Book
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
The demand for erythropoietic protoporphyria (EPP) treatment procedures is predicted to rise at a >7% CAGR through 2029.
The global EPP treatment market is growing due to the rapidly rising unmet need for innovative therapies for the treatment of erythropoietic protoporphyria (EPP).
Erythropoietic protoporphyria treatment market expansion in emerging nations is anticipated to be constrained by higher treatment costs and a lack of uniform healthcare facilities.
Need An Exclusive Report For Your Unique Requirement?